vida: extract claims from 2025-12-17-weight-watchers-med-plus-glp1-program-2026-no-cgm-integration
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
- Source: inbox/queue/2025-12-17-weight-watchers-med-plus-glp1-program-2026-no-cgm-integration.md - Domain: health - Claims: 0, Entities: 0 - Enrichments: 2 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
This commit is contained in:
parent
090f10af17
commit
701c0acff4
2 changed files with 11 additions and 1 deletions
|
|
@ -52,3 +52,10 @@ WeightWatchers' post-bankruptcy (May 2025) strategy shows selective CGM deployme
|
||||||
**Source:** Noom press releases + Pharmaceutical Commerce, December 2025
|
**Source:** Noom press releases + Pharmaceutical Commerce, December 2025
|
||||||
|
|
||||||
Noom's December 2025 'Proactive Health Microdose GLP-1Rx' program ($149/month) combines microdosed GLP-1 with at-home biomarker testing every four months, representing a distinct atoms-to-bits integration strategy from Omada's continuous CGM monitoring. This periodic biomarker testing approach (quarterly) vs. continuous monitoring (daily) represents two different physical-to-digital integration strategies with different cost/adherence tradeoffs. Noom achieved $100M revenue run-rate within four months of launching GLP-1 programs in September 2024, demonstrating that periodic biomarker testing can be commercially viable as a physical integration layer.
|
Noom's December 2025 'Proactive Health Microdose GLP-1Rx' program ($149/month) combines microdosed GLP-1 with at-home biomarker testing every four months, representing a distinct atoms-to-bits integration strategy from Omada's continuous CGM monitoring. This periodic biomarker testing approach (quarterly) vs. continuous monitoring (daily) represents two different physical-to-digital integration strategies with different cost/adherence tradeoffs. Noom achieved $100M revenue run-rate within four months of launching GLP-1 programs in September 2024, demonstrating that periodic biomarker testing can be commercially viable as a physical integration layer.
|
||||||
|
|
||||||
|
|
||||||
|
## Supporting Evidence
|
||||||
|
|
||||||
|
**Source:** HIT Consultant Dec 2025, WW Clinic review 2026
|
||||||
|
|
||||||
|
WeightWatchers Med+ program (launched December 2025, 7 months post-bankruptcy) excludes CGM integration for general obesity/GLP-1 program despite having CGM for diabetes tier. WW chose behavioral depth + prescribing quality over physical data integration. This creates a direct market test: WW (behavioral-only for general obesity) vs Omada (CGM-integrated, profitable 2025 IPO). WW's 21% weight loss claim relies on internal study (n=3,250), not externally validated. The one-time metabolic lab work is a single physical data capture, not continuous monitoring like Omada's CGM.
|
||||||
|
|
|
||||||
|
|
@ -7,10 +7,13 @@ date: 2025-12-17
|
||||||
domain: health
|
domain: health
|
||||||
secondary_domains: []
|
secondary_domains: []
|
||||||
format: thread
|
format: thread
|
||||||
status: unprocessed
|
status: processed
|
||||||
|
processed_by: vida
|
||||||
|
processed_date: 2026-05-01
|
||||||
priority: medium
|
priority: medium
|
||||||
tags: [WeightWatchers, GLP-1, CGM, atoms-to-bits, Belief4, obesity-management, behavioral-support, telehealth]
|
tags: [WeightWatchers, GLP-1, CGM, atoms-to-bits, Belief4, obesity-management, behavioral-support, telehealth]
|
||||||
intake_tier: research-task
|
intake_tier: research-task
|
||||||
|
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||||
---
|
---
|
||||||
|
|
||||||
## Content
|
## Content
|
||||||
Loading…
Reference in a new issue